Web: | mayocliniclabs.com |
---|---|
Email: | mcl@mayo.edu |
Telephone: | 800-533-1710 |
International: | +1 855-379-3115 |
Values are valid only on day of printing. |
Genetic confirmation of hereditary angioedema (HAE) type III with the identification of an alteration in the F12 gene known or suspected to cause the condition
Testing for close family members of an individual with an HAE type III diagnosis
Genetic confirmation of factor XII deficiency with the identification of an alteration in the F12 known or suspected to cause the condition
This test is not intended for prenatal diagnosis
This test detects pathogenic alterations in the F12 gene to delineate the underlying molecular defect in a patient with a laboratory diagnosis of factor XII deficiency or hereditary angioedema with normal C1 inhibitor (FXII-HAE).
The gene target for this test is:
Gene name (transcript): F12 (GRCh37 [hg19] NM_000505)
Chromosomal location: 5q35.3
Factor XII deficiency:
Special coagulation testing for factor XII (F_12 / Coagulation Factor XII Activity Assay, Plasma) should be performed prior to any genetic testing.
Genetic testing for factor XII deficiency may be considered if:
-Factor XII activity is reduced (less than 55% of normal)
-Acquired causes of factor XII have been excluded
Hereditary angioedema type III (FXII-HAE):
An international consortium has established a testing and diagnostic algorithm for the identification of hereditary angioedema (HAE) type III.(1)
Custom Sequence Capture and Targeted Next-Generation Sequencing (NGS) Followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing When Appropriate